Immunotherapy in Elderly Cancer Patients

tibbi onkoloji ozel 13-4 kapak

Ali GÖKYERa, Ahmet KÜÇÜKARDAa, İrfan ÇİÇİNa

aTrakya Üniversitesi Tıp Fakültesi, Tıbbi Onkoloji BD, Edirne, TÜRKİYE

ABSTRACT
Two-thirds of all new cancer diagnoses are made in persons over the age of 65 years. It is unclear if age affects patient respons to immunotherapy, which is increasingly becoming first-line therapy in advanced stages of different tumor types. As a result of data obtained from different immunotherapy studies, it was seen that advanced age did not change safety and response. In these studies, it was found that drugs were generally in low toxicity profile and well tolerated in elderly and young patient subgroups. However, there are drug-specific differences for immune check-point inhibition in comparison of young patients and overall survival and progression-free survival rates in elderly individuals. Further studies should be conducted on patients who respond to and do not give medication to optimize the use of immunotherapy in elderly patients.
Keywords: Immunotherapy; cancer survivors; drug-related side effects and adverse reactions

Referanslar

  1. Song L, Kim YH, Chopra RK, Proust JJ, Nagel JE, Nordin AA, et al. Age-related effects in T cell activation and proliferation. Exp Gerontol. 1993;28(4-5):313-21. [Crossref]  [PubMed]
  2. Haynes BF, Sempowski GD, Wells AF, Hale LP. The human thymus during aging. Immunol Res. 2000;22(2-3):253-61. [Crossref]  [PubMed]
  3. Taub DD, Longo DL. Insights into thymic aging and regeneration. Immunol Rev. 2005; 205:72-93. [Crossref]  [PubMed]
  4. Bruunsgaard H, Pedersen BK. Age-related inflammatory cytokines and disease. Immunol Allergy Clin North Am. 2003;23(1):15-39. [Crossref]  [PubMed]
  5. Spano J, Chaibi P, Vignot S, Thery JC, de La Motte Rouge T, Gil-Delgado M, et al. Age-related changes in plasma levels of inflammatory and angiogenic cytokins in patients with cancer. J Clin Oncol. 2011;29(15_suppl): e19699. [Crossref]
  6. Weiss SA, Han J, Darvishian F, Tchack J, Han SW, Malecek K, et al. Impact of aging on host immune response and survival in melanoma: an analysis of 3 patient cohorts. J Transl Med. 2016;14(1):299. [Crossref]  [PubMed]  [PMC]
  7. Tomihara K, Curiel TJ, Zhang B. Optimization of immunotherapy in elderly cancer patients. Crit Rev Oncog. 2013;18(6):573-83. [Crossref]  [PubMed]  [PMC]
  8. Bouchlaka MN, Sckisel GD, Chen M, Mirsoian A, Zamora AE, Maverakis E, et al. Aging predisposes to acute inflammatory induced pathology after tumor immunotherapy. J Exp Med. 2013;210(11):2223-37. [Crossref]  [PubMed]  [PMC]
  9. Muro K, Chung HC, Shankaran V, Geva R, Catenacci D, GuptaS, et al. Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, openlabel,phase 1b trial. Lancet Oncol. 2016;17(6):717-26. [Crossref]  [PubMed]
  10. Seiwert TY, Burtness B, Mehra R, Weiss J, Berger R, Eder JP, et al. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial. Lancet Oncol. 2016;17(7):956-65. [Crossref]  [PubMed]
  11. Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015;372(21):2018-28. [Crossref]  [PubMed]
  12. Mullard A. FDA approvals for the first 6 months of 2016. Nat Rev Drug Discov. 2016;15(8):523. [Crossref]
  13. Nishijima TF, Muss HB, Shachar SS, Moschos SJ. Comparison of efficacy of immune checkpoint inhibitors (ICIs) between younger and older patients: a systematic review and metaanalysis. Cancer Treat Rev. 2016;45:30-7. [Crossref]  [PubMed]
  14. Landre T, Taleb C, Nicolas P, Des Guetz G. Is there a clinical benefit of anti-PD-1 in patients older than 75 years with previously treated solid tumour? J Clin Oncol. 2016;34(suppl; abstr 3070). [Crossref]
  15. Robert C, Thomas L, Bondarenko I, O'Day S, Weber J, Garbe C, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011;364(26):2517-26. [Crossref]  [PubMed]
  16. Kwon ED, Drake CG, Scher HI, Fizazi K, Bossi A, van den Eertwegh AJ, et al. Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 2014;15(7):700-12. [Crossref]  [PubMed]
  17. Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015;372(4):320-30. [Crossref]  [PubMed]
  18. Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med. 2015;372(26):2521-32. [Crossref]  [PubMed]
  19. Reck M, Luft A, Szczesna A, Havel L, Kim SW, Akerley W, et al. Phase III randomized trial of ipilimumab plus etoposide and platinum versus placebo plus etoposide and platinum in extensive-stage small-cell lung cancer. J Clin Oncol. 2016;34:3740-8. [Crossref]  [PubMed]
  20. Ferris RL, Blumenschein G Jr, Fayette J, Guigay J, Colevas AD, Licitra L, et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med. 2016;375(19):1856-67. [Crossref]  [PubMed]  [PMC]
  21. Bellmunt J, de Wit R, Vaughn DJ, Fradet Y, Lee JL, Fong L, et al. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med. 2017;376(11): 1015-26. [Crossref]  [PubMed]  [PMC]
  22. Ascierto PA, Del Vecchio M, Robert C, Mackiewicz A, Chiarion- Sileni V, Arance A, et al. Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double blind, multicentre, phase 3 trial. Lancet Oncol. 2017;18:611-22. [Crossref]  [PubMed]
  23. Escudier B, Sharma P, McDermott DF, George S, Hammers HJ, Srinivas S, et al. CheckMate 025 randomized phase 3 study: outcomes by key baseline factors and prior therapy for nivolumab versus everolimus in advanced renal cell carcinoma. Eur Urol. 2017. [Crossref]  [PubMed]
  24. Johnpulle RAN, Conry RM, Sosman JA, Puzanov I, Johnson DB. Responses to immune checkpoint inhibitors in nonagenarians. OncoImmunology. 2016;5(11):e1234572. [Crossref]  [PubMed]  [PMC]
  25. Chiarion Sileni V, Pigozzo J, Ascierto PA, Grimaldi AM, Maio M, Di Guardo L, et al. Efficacy and safety of ipilimumab in elderly patients with pretreated advanced melanoma treated at Italian centres through the expanded access programme. J Exp Clin Cancer Res. 2014;33:30. [Crossref]  [PubMed]  [PMC]
  26. Nabhan C, Sartor O, Cooperberg MR, Armstrong AJ, Vacirca JL, Concepcion RS, et al. Sipuleucel-T in metastatic castrationresistant prostate cancer (mCRPC) patients $80 years-old: data from PROCEED. J Clin Oncol. 2014;32 Suppl 4:64. [Crossref]
  27. Kochenderfer JN, Dudley ME, Kassim SH, Somerville RP, Carpenter RO, StetlerStevenson M, et al. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an antiCD19 chimeric antigen receptor. J Clin Oncol. 2015;33(6):540-9. [Crossref]  [PubMed]  [PMC]
  28. Andtbacka RH, Kaufman HL, Collichio F, Amatruda T, Senzer N, Chesney J, et al. Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J Clin Oncol. 2015;33(25):2780- 8. [Crossref]  [PubMed]
  29. Harrington KJ, Andtbacka RH, Collichio F, Downey G, Chen L, Szabo Z, et al. Efficacy and safety of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in patients with stage IIIB/C and IVM1a melanoma: subanalysis of the Phase III OPTiM trial. Onco Targets Ther. 2016;9:7081-93. [Crossref]  [PubMed]  [PMC]
  30. Noonan AM, Farren MR, Geyer SM, Huang Y, Tahiri S, Ahn D, et al. Randomized phase 2 trial of the oncolytic virus pelareorep (Reolysin) in upfront treatment of metastatic pancreatic adenocarcinoma. Mol Ther. 2016;24(6):1150-8. [Crossref]  [PubMed]  [PMC]